^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    5T4-targeted antibody-drug conjugate

    Related drugs:
    3ms
    JK06.1.01: A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unresectable Locally Advanced or Metastatic Cancer (2024-512421-92-00)
    P1/2, N=305, Recruiting, Salubris Biotherapeutics Inc. | N=210 --> 305
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 positive • EGFR mutation • HR positive • HER-2 negative • ALK mutation • ROS1 fusion • ESR1 mutation • HER-2 negative + HR negative • HER-2 negative + HR positive + ESR1 mutation
    5ms
    JK06.1.01: Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1/2, N=255, Recruiting, Salubris Biotherapeutics Inc | N=155 --> 255
    Enrollment change • First-in-human
    5ms
    5-STAR 1-01: First in Human Study of TUB-030 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=250, Recruiting, Tubulis GmbH | N=130 --> 250
    Enrollment change • First-in-human
    6ms
    5-STAR 1-01: A Study to Test the Safety and Effects of a New Cancer Drug (TUB-030) in Patients with Advanced Solid Tumors (2025-522517-35-00)
    P1/2, N=90, Recruiting, Tubulis GmbH
    New P1/2 trial • First-in-human
    |
    MSI (Microsatellite instability) • CD4 (CD4 Molecule)
    |
    MSI-H/dMMR
    9ms
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, NeoTX Therapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    9ms
    ACR246-101: An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=77, Recruiting, Hangzhou Adcoris Biopharmacy Co., Ltd | Trial completion date: Jan 2026 --> Nov 2026 | Trial primary completion date: Jun 2025 --> May 2026
    Trial completion date • Trial primary completion date
    12ms
    Preclinical characterization of XB010: a novel antibody-drug conjugate for the treatment of solid tumors that targets tumor-associated antigen 5T4. (PubMed, Mol Cancer Ther)
    XB010 is a novel anti-5T4 ADC that exhibits potent anti-tumor activity, inhibiting cancer cell growth in vitro and tumor growth in various in vivo models, with an acceptable toxicity profile. These findings support the evaluation of XB010 in clinical studies.
    Preclinical • Journal
    |
    TPBG (Trophoblast Glycoprotein)
    over1year
    Naptumomab Estafenatox in Combination with Durvalumab in Subjects with Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (clinicaltrials.gov)
    P1, N=120, Recruiting, NeoTX Therapeutics Ltd. | Active, not recruiting --> Recruiting | N=60 --> 120 | Trial completion date: Oct 2026 --> Mar 2027 | Trial primary completion date: Oct 2026 --> Mar 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    over1year
    5-STAR 1-01: First in Human Study of TUB-030 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=130, Recruiting, Tubulis GmbH | Not yet recruiting --> Recruiting
    Enrollment open
    almost2years
    ACR246-101: An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=77, Recruiting, Hangzhou Adcoris Biopharmacy Co., Ltd | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Oct 2024 | Trial primary completion date: Jan 2025 --> Jun 2025
    Enrollment open • Trial initiation date • Trial primary completion date • Metastases
    almost2years
    A Study of JK06 in Patients with Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1/2, N=155, Recruiting, Salubris Biotherapeutics Inc
    New P1/2 trial • Metastases
    almost2years
    First in Human Study of TUB-030 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=130, Not yet recruiting, Tubulis GmbH
    New P1/2 trial